AJP - Heart BIOPAC complete lab solutions
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 279: H528-H535, 2000;
0363-6135/00 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (29)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Muscará, M. N.
Right arrow Articles by Wallace, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muscará, M. N.
Right arrow Articles by Wallace, J. L.
Vol. 279, Issue 2, H528-H535, August 2000

Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats

Marcelo N. Muscará, Webb McKnight, Fina Lovren, Christopher R. Triggle, Giuseppe Cirino, and John L. Wallace

Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, T2N 4N1, Canada; and Department of Experimental Pharmacology, University of Naples, Naples, Italy 08131

Nonsteroidal anti-inflammatory drugs have been reported to exacerbate hypertension. In this study, we tested the hypothesis that a nitric oxide-releasing derivative of naproxen would ameliorate hypertension in the rat. Hypertension was induced by partially occluding one renal artery (the "2K,1C" model), and 2 wk later the rats started receiving naproxen, the nitric oxide-releasing derivative HCT-3012, or vehicle each day for 2 wk. Naproxen significantly exacerbated the hypertension. HCT-3012 significantly reduced blood pressure relative to both the naproxen- and vehicle-treated groups. Both naproxen and HCT-3012 markedly suppressed whole blood thromboxane B2 synthesis. In studies of anesthetized rats, naproxen significantly enhanced the late hypertensive response to endothelin-1 and significantly blunted the early hypotensive response. In contrast, HCT-3102 did not affect either response to endothelin-1. In vitro, HCT-3012 significantly reduced the responsiveness of aortic rings to the contractile effects of phenylephrine. These studies suggest that HCT-3012 reduces blood pressure in hypertensive rats, not simply through the vasodilatory actions of the nitric oxide it releases, but through alterations in the responsiveness of the vasculature to endogenous pressor agents.

prostaglandin; anti-inflammatory; endothelin


This article has been cited by other articles:


Home page
 The Journal of RheumatologyHome page
J. KARLSSON, A. PIVODIC, D. AGUIRRE, and T. J. SCHNITZER
Efficacy, Safety, and Tolerability of the Cyclooxygenase-Inhibiting Nitric Oxide Donator Naproxcinod in Treating Osteoarthritis of the Hip or Knee
J Rheumatol, June 1, 2009; 36(6): 1290 - 1297.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
M. S. Goligorsky
Endothelial cell dysfunction: can't live with it, how to live without it
Am J Physiol Renal Physiol, May 1, 2005; 288(5): F871 - F880.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
C J Hawkey, J I Jones, C T Atherton, M M Skelly, J R Bebb, U Fagerholm, B Jonzon, P Karlsson, and I T Bjarnason
Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans
Gut, November 1, 2003; 52(11): 1537 - 1542.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online